There is a growing body of evidence that TNF inhibitors may have a stronger impact on the activation of latent tuberculosis than other immune modulating drugs. However differences between individual inhibitors, dosages, and concurrently used immune suppressive medications all may play a role in the incidence of tuberculosis in patients treated with TNF-alpha inhibitors.

The European Medicines Evaluation Agency has issued recommendations for the use of Centocor Inc.'s Remicade infliximab in patients with Crohn's disease and rheumatoid arthritis (RA), following 28 worldwide reports of serious tuberculosis (TB) infections in patients treated with infliximab (see BioCentury Extra, Tuesday Jan. 2). Centocor Inc. is a subsidiary of Johnson & Johnson (JNJ, New Brunswick, N.J.).